While cytotoxic CD8+ T cells are well-established to correspond with beneficial outcomes, we were surprised to record a benefit of CD163+CD16a+ cells, since the CD163 marker is typically associated with M2 macrophages and poorer anti-cancer functions (14). This evidence concerns the gene FCGR3A and cancer.